These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 30998396)

  • 21.
    Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
    J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
    Price MJ; Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Genetic variability in the efficacy of clopidogrel].
    Kristensen KE; Rasmussen HB; Hansen PR
    Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clopidogrel pharmacogenetics: associations between genotype and stent thrombosis risk in patients with stent placement.
    Ferrari M; Tozzi M; Marino F; Tarallo A; Riva F; Mirabile M; Castelli P; Cosentino M
    J Cardiovasc Med (Hagerstown); 2019 Jan; 20(1):46-48. PubMed ID: 30531616
    [No Abstract]   [Full Text] [Related]  

  • 27. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
    González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
    Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomics of clopidogrel: evidence and perspectives.
    Yin T; Miyata T
    Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
    Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T
    Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.
    Adamiak-Giera U; Czerkawska A; Olędzki S; Kurzawski M; Safranow K; Jastrzębska M; Gawrońska-Szklarz B
    Pharmacol Rep; 2021 Apr; 73(2):583-593. PubMed ID: 33270185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
    Duconge J; Hernandez-Suarez DF
    Curr Clin Pharmacol; 2017; 12(1):11-17. PubMed ID: 28245774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotype-Guided Strategy for P2Y
    Kheiri B; Simpson TF; Osman M; Kumar K; Przybylowicz R; Merrill M; Golwala H; Rahmouni H; Cigarroa JE; Zahr F
    JACC Cardiovasc Interv; 2020 Mar; 13(5):659-661. PubMed ID: 32139230
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
    Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.
    Ayesh BM; Al-Astal IR; Yassin MM
    Int J Clin Pharm; 2019 Feb; 41(1):96-103. PubMed ID: 30656556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.